Bone mineral density in later life largely depends on the peak bone mass achieved in
adolescence or young adulthood. A reduced bone density is associated with increased …

Objective. Several studies have reported beneficial effects of bisphosphonates in children
with osteogenesis imperfecta (OI); however, these studies have differed in the protocols they …

This systematic review of the effects of bisphosphonate treatment in children with
osteogenesis imperfecta was conducted using the American Academy for Cerebral Palsy …

Osteogenesis imperfecta (OI), an inherited connective tissue disorder of remarkable clinical
variability, is caused by a quantitative or qualitative defect in collagen synthesis and is …

OBJECTIVE: To evaluate prospectively the efficacy of bisphosphonate treatment in infants
with severe forms of osteogenesis imperfecta (OI). STUDY DESIGN: Of 10 children (6 …

Pediatric Bone is the first book to be published to deal exclusively with the biology and
diseases of bone as they affect children. Rapid advances have been made in our …

Alendronate, a bisphosphonate drug, has shown promise in reducing remodeling and bone
loss in postmenopausal osteoporosis. Alendronate acts directly on the osteoclast, inhibiting …

Considerable progress has been made in many aspects of osteogenesis imperfecta. The
international Sillence classification of osteogenesis imperfecta is being expanded to include …

Severe forms of osteogenesis imperfecta (OI) are characterised by osteoporosis with
multiple fractures, deformity, progressive loss of mobility and chronic bone pain …

Bisphosphonates are now widely used to treat children with osteogenesis imperfecta (OI).
However, there are few published data following the initial evolution of changes in bone …